Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers
Open accessPublished version of a preprint
The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Antiangiogenic tyrosine kinase inhibitors (TKI) that target VEGF receptor-2 (VEGFR2) have not been effective as adjuvant treatments for micrometastatic disease in phase III clinical trials. Angiopoietin-2 (Ang2) is a proangiogenic and proinflammatory vascular destabilizer that cooperates with VEGF. The purpose of this study was to test whether CVX-060 (an Ang2-specific CovX-body) can be combined with VEGFR2-targeting TKIs (sunitinib or regorafenib) to successfully treat postsurgical metastatic disease in multiple orthotopically implanted human tumor xenograft and syngeneic murine tumor models. In the MDA-MB-231.LM2-4 human breast cancer model, adjuvant sunitinib was ineffective, whereas adjuvant CVX-060 delayed the progression of pulmonary or distant lymphatic metastases; however, overall survival was only improved with the adjuvant use of a VEGF-A/Ang2-bispecific CovX-body (CVX-241) but not when CVX-060 is combined with sunitinib. Adjuvant CVX-241 also showed promise in the EMT-6/CDDP murine breast cancer model, with or without an immune checkpoint inhibitor (anti-PD-L1). In the RENCA model of mouse renal cancer, however, combining CVX-060 with sunitinib in the adjuvant setting was superior to CVX-241 as treatment for postsurgical lung metastases. In the HCT116 and HT29 xenograft models of colorectal cancer, both CVX-060 and regorafenib inhibited liver metastases. Overall, our preclinical findings suggest differential strategies by which Ang2 blockers can be successfully combined with VEGF pathway targeting in the adjuvant setting to treat micrometastatic disease—particularly, in combination with VEGF-A blockers (but not VEGFR2 TKIs) in resected breast cancer; in combination with VEGFR2 TKIs in resected kidney cancer; and as single agents or with VEGFR2 TKIs in resected colorectal cancer. Cancer Res; 76(23); 6988–7000. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“dual VEGF–ANG2 blockade prolonged survival compared with anti-VEGF or anti-ANG2 monotherapy in mouse models of glioblastoma35,36, melanoma16, pancreatic neuroendocrine tumours (PNETs)16, and metastatic16,90 or early stage (resected) breast cancer90.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [90]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the therapeutic benefits of dual VEGF–ANG2 blockade seem to be conferred through the lymphoid (for example, in breast and colon tumour models16) and/or myeloid cell populations (in both central nervous system (CNS) and non-CNS tumour models16,35,36,90).”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [90]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“possibly owing to inhibitory effects on multiple kinases with diverse activities90.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [90]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with the pan-VEGFR TKI sunitinib in combination with an ANG2-neutralizing antibody, however, led to a decreased frequency of lung metastases from orthotopic RENCA tumours”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [90]
Experimental — accuracy not yet measuredIn the citing paper
“a survival benefit was not observed in a model of metastatic RCC (RENCA) with VEGF–ANG2-neutralizing therapy90.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of platelet-derived growth factors in physiology and medicine
Andrae, J., Gallini, R., & Betsholtz, C. (2008) · Genes & Development · doi:10.1101/gad.1653708 · Cited by 2,438 · cited 14×
“7C), while the EPO elevation was most effectively counteracted by sunitinib+CVX-060 (Fig.”
BackgroundInfluentialPàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339 · cited 1×
“The negative adjuvant trial results (Supplemental Table S1) have also incited the following questions: In the AVANT trial, could anti-VEGF therapy have inadvertently increased the malignancy of residual disease (1), akin to how in preclinical studies such therapies can have both tumor growth-inhibiting as well as pro-…”
BackgroundVessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195 · cited 1×
“Second, Ang2 has an implicated role in host vessel co-option (13).”
BackgroundAccelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709 · cited 4×
“The negative adjuvant trial results (Supplemental Table S1) have also incited the following questions: In the AVANT trial, could anti-VEGF therapy have inadvertently increased the malignancy of residual disease (1), akin to how in preclinical studies such therapies can have both tumor growth-inhibiting as well as pro-…”
BackgroundMethodSelf-citationProlonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318
Epigenetic and genetic features of 24 colon cancer cell lines
Ahmed, D., Eide, P. W., Eilertsen, I. A., Danielsen, S. A., Eknæs, M., Hektoen, M., Lind, G. E., & Lothe, R. A. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.35 · Cited by 910 · cited 1×
“Using two luciferase-tagged human colorectal carcinoma cell lines – HCT116, a TP53wildtype cell line with ‘microsatellite instability’ (MSI), and HT29, a TP53-mutant ‘microsatellite stable’ (MSS) cell line (36) – we assessed the effects of CVX-060 versus regorafenib on CRC primary tumors and metastases.”
BackgroundMolecular basis for sunitinib efficacy and future clinical development
Faivre, S., Demetri, G., Sargent, W., & Raymond, E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2380 · Cited by 721 · cited 10×
“Our RENCA model suggests potential efficacy of combining an anti-Ang2 agent (CVX-060) with lowered doses of antiangiogenic TKIs (ideally ones that target both VEGFR2 and PDGFRβ, e.g., sunitinib) in the adjuvant setting of RCC.”
BackgroundInfluentialHaas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., Jewett, M., Dutcher, J. P., Atkins, M. B., Pins, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00559-6 · Cited by 630 · cited 1×
“Interestingly, however, the survival analyses sometimes initially appeared favorable for the antiangiogenic therapy groups, but these transient advantages faded over time after adjuvant therapy was stopped (1-3).”
BackgroundCooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.024 · Cited by 530 · cited 1×
“5 (‘hijacking’) of existing host blood vessels more relevant when metastatic tumor cells colonize vascular-rich distant organs (6-8)? In the adjuvant antiangiogenic TKI trials, could secondary targeting of the PDGFR and VE-cadherin pathways have compromised the main activity of these broad-spectrum TKIs stemming from…”
Backgroundde Gramont, A., Van Cutsem, E., Schmoll, H.-J., Tabernero, J., Clarke, S., Moore, M. J., Cunningham, D., Cartwright, T. H., Hecht, J. R., Rivera, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70509-0 · Cited by 529 · cited 3×
“The negative adjuvant trial results (Supplemental Table S1) have also incited the following questions: In the AVANT trial, could anti-VEGF therapy have inadvertently increased the malignancy of residual disease (1), akin to how in preclinical studies such therapies can have both tumor growth-inhibiting as well as pro-…”
Background
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 657
Self-citationNormalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530
“In other tumors, dual inhibition promotes T cell effector function and increases efficacy of ICBs (82), in some cases despite inducing vessel regression (83).”
BackgroundInfluentialKuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S., & Reynolds, A. R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0181-9 · Cited by 446
Self-citation
Metadata
- Authors
- Wu, F. T. H., Man, S., Xu, P., Chow, A., Paez-Ribes, M., Lee, C. R., Pirie-Shepherd, S. R., Emmenegger, U., & Kerbel, R. S.
- Affiliations
- University of Toronto (CA)
- Sunnybrook Research Institute (CA)
- 2Biological Sciences Platform, Sunnybrook Research Institute, Toronto, Canada.
- Pfizer (United States) (US)
- Corresponding author
- Kerbel, Robert S.
- Venue
- Cancer Research
- Published
- 2016-11-30
- Volume
- 76
- Issue
- 23
- Pages
- 6988-7000
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC5633081
- OpenAlex
- W2521128555
- Cited by
- 58
- References
- 50
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 3 · 2023: 8 · 2022: 4 · 2021: 6 · 2020: 8 · 2019: 6 · 2018: 8 · 2017: 4 · 2016: 1
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- angiopoietin-2, VEGF-A, VEGFR2, anti-angiogenic therapy, adjuvant therapy, micrometastases, sunitinib, regorafenib, breast cancer, colorectal cancer, kidney cancer, lung metastasis, liver metastasis, immune checkpoint inhibitors, PD-L1 inhibitors
- MeSH terms
- Animals, Breast Neoplasms, Female, Humans, Kidney Neoplasms, Mice, Inbred BALB C, Colorectal Neoplasms, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Angiopoietin-2, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-0888
- The paper
- Wu, F. T. H., Man, S., Xu, P., Chow, A., Paez-Ribes, M., Lee, C. R., Pirie-Shepherd, S. R., Emmenegger, U., & Kerbel, R. S. (2016). Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-0888
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.